Homocysteine and C-reactive Protein Levels in Women with Polycystic Ovary Syndrome

Murat Gözüküçük*, Aslı Yarcı Gürsoy1, Emre Destegül3, Salih Taşkın4, Hakan Şatıroğlu4
1Department of Obstetrics and Gynecology, Ankara Training and Research Hospital, Ankara, 2Department of Obstetrics and Gynecology, Adana City Hospital, Adana, 3Department of Obstetrics and Gynecology, Ufuk University Medical Faculty, 4Department of Obstetrics and Gynecology, Ankara University Medical Faculty, Ankara, Turkey

Abstract

Objectives: Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in infertile women characterized by both reproductive and metabolic dysfunctions of different degrees. Furthermore, it has been associated with increased cardiovascular disease (CVD) risk and related long-term health sequela. The aim of this study is to evaluate serum homocysteine (Hcy) and C-reactive protein (CRP) levels in women with PCOS and to evaluate their relationship with clinical and laboratory parameters in women with PCOS.

Materials and Methods: The prospective single-center study included 45 women with PCOS (study group) and 41 control subjects. Demographic variables and Hcy, CRP, fasting blood glucose, insulin, follicle-stimulating hormone, luteinizing hormone, estradiol, total and free testosterone, dehydroepiandrosterone sulfate, thyroid-stimulating hormone levels, and lipid profiles of the subjects were recorded. Homeostatic model assessment for insulin resistance (HOMA-IR) indexes were calculated.

Results: Fasting plasma glucose, insulin, HOMA-IR, free and total testosterone levels, and clinical hirsutism were significantly higher in the study group. There was no statistically significant difference in lipid profile between groups. Hcy and CRP levels were higher in the study group, which was not statistically significantly different (P > 0.05).

Conclusion: Some of the parameters that are correlated with CVD risk were found to be higher in women with PCOS, although the difference for Hcy and CRP did not reach statistical significance. However, the current study reveals that the CVD risk associated with PCOS deserves more comprehensive prospective studies with long-term outcomes.

Keywords: C-reactive protein, homocysteine, polycystic ovary syndrome

Introduction

The prevalence of polycystic ovary syndrome (PCOS) is 5%–15% in reproductive age women according to Rotterdam criteria that include chronic menstrual dysfunction, clinical or biochemical hyperandrogenism, and polycystic ovaries confirmed by ultrasonography (≥10 follicles and ≥10 ml ovarian volume).[1] It is one of the most common etiological factors for female anovulatory infertility but also accompanied by metabolic disorders such as obesity, insulin resistance, gestational diabetes mellitus, Type II diabetes mellitus, and long-term adverse health outcomes.[2]

There is an increased risk of cardiovascular disease (CVD) in women with PCOS. Not only myocardial infarction is approximately seven times higher in this population,[3] but also extensive coronary artery disease and carotid atherosclerosis are more common in women with PCOS.[4,5] CVD risk factors such as dyslipidemia, diabetes mellitus, and obesity have also been more common in women with PCOS. However, it is not known whether increased cardiovascular events in women with PCOS are due to accompanying...
obesity, higher body mass index (BMI), or other metabolic disorders independently.

Homocysteine (Hcy) is a nonessential amino acid, which is not present in the daily diet but synthesized in our body from methionine, another amino acid produced by metabolization of proteins. Hcy, once produced from methionine, can be removed in two ways which are reconversion to methionine by remethylation or to cysteine by transsulfuration.

Hyperhomocysteinemia is associated with an increased risk of aging-related diseases such as atherosclerotic and thromboembolic events besides CVDs.[6-8] Hcy is hypothesized to increase CVD risk, by both its effects on vascular wall structures and blood coagulation system.[7,9,10] Therefore, hyperhomocysteinemia has been accepted as one of the CVD risk factors. Independent of the Framingham risk scoring system, which is frequently used to estimate CVD risk, it is proposed that, for each increment in Hcy concentrations of 5 µmol, the risk of cardiovascular events increases by about 20%.[11] In addition, hyperhomocysteinemia reduces the synthesis of nitric oxide in endothelial cells. Nitric oxide plays a role in almost all stages of female reproductive processes, such as ovulation, early embryo development, implantation, pregnancy, and birth contractions.[12] From this point of view, higher Hcy levels might be correlated with adverse fertility outcomes.[13]

C-reactive protein (CRP) is a well-known marker for infection but also used to follow up low-grade chronic inflammation which provides the pathophysiological basis for atherosclerosis and is a good predictor of vascular events. CRP causes atherogenesis directly via adhesion molecule expression and complement activation.[14] Therefore, CRP has been accepted as one of the criteria for cardiovascular risk assessment by the Centers for Disease Control and Prevention and American Heart Association[15,16] and also different cutoff values for determination and classification as mild, moderate, and high risks have been defined.[17] Increased CRP levels are observed in women with PCOS reflecting the chronic inflammatory aspect of the disease. This increased inflammatory activity can theoretically affect folliculogenesis, and ovulation as the anovulation is the main defect of patients with PCOS, resulting in infertility.[18]

Although, women with PCOS are mostly presented with anovulatory infertility, PCOS is also associated with long-term adverse outcomes such as metabolic syndrome and CVD. Many markers indicating increased metabolic activity including Hcy and CRP levels have been shown to increase in women with PCOS necessitating further research to overcome the long-term adverse health outcomes in these women. From this point of view, in our study, we aimed to evaluate levels of two different markers acting through different pathways – Hcy: associated with endothelial inflammation and CRP: associated with chronic low-grade inflammation – and to evaluate their relationship with clinical and laboratory parameters in women with PCOS.

**Materials and Methods**

The study was performed in the Obstetrics and Gynecology Outpatient Clinic of Ankara University Hospital. It was a prospective, single-center study. Our study population comprised two groups of women (45 with PCOS and 41 age- and BMI-matched controls). The Ethical Committee of the University Hospital approved the study (113-2990), and informed consent was taken from all participants. Among 100 patients, data of 86 who accepted to participate in the study were included. The study group (n = 45) consisted of women who were diagnosed with PCOS according to the Rotterdam criteria.[19] Furthermore, subgroup analysis of the two groups regarding BMI, homeostatic model assessment for insulin resistance (HOMA-IR), and the presence of clinical hirsutism was held. Exclusion criteria were the presence of hyperprolactinemia, thyroid dysfunction, adrenal dysfunction, diabetes mellitus, hypertension, pregnancy, and smoking. None of the participants were on hormonal medications during the study period.

Venous blood samples were collected (2nd or 3rd day) during the menstrual cycle after overnight fasting for at least 12 h. In cases with oligo-anovulation, blood samples were obtained after progesterone withdrawal bleeding. Levels of fasting blood glucose, insulin, and hormone profile (follicle-stimulating hormone, luteinizing hormone, estradiol [E2], total and free testosterone [total-T and free-T, respectively], dehydroepiandrosterone sulfate, and thyroid-stimulating hormone) were evaluated. Fasting insulin and fasting plasma glucose (FPG) levels were used for the calculation of HOMA-IR (insulin × glycemia in µmol/L/22.5).[20] Insulin resistance was accepted as HOMA-IR ≥2.1.[21] Lipid profiles (total cholesterol, low-density lipoprotein, high-density lipoprotein [HDL], and very-low-density lipoprotein) of two groups were recorded. CRP levels were evaluated by competitive ELISA technique (Calbiochem-Novabiochem, California, USA), and Hcy levels were measured by fluorescence polarization immunoassay (IMX System, Abbott Diagnostics, USA). Clinical hirsutism was evaluated by the modified Ferriman–Gallwey scoring system, and a total score of 8 or over was defined as clinical hirsutism.[22] Biochemical hirsutism was defined as total testosterone level >80 ng/dL or DHEAS level >350 ng/Dl.[22]

**Statistical analysis**

Statistical analysis was performed using SPSS for Windows version 22.0 (SPSS Inc., Chicago, IL, USA). Data were shown as mean ± standard deviation or median (minimum–maximum)
and clinical hirsutism (n = 13 vs. n = 0, P < 0.001, respectively) were statistically significantly higher in the study group.

There was no statistically significant difference between lipid profiles (total cholesterol, low-density lipoprotein, HDL, and very-low-density lipoprotein) between the two groups (P > 0.05). There was no statistically significant difference in Hcy and CRP levels between the study and control groups, although Hcy and CRP levels were higher in the study group (8.7 [4.8–18] vs. 7.7 [5.5–18.6] μmol/L, P = 0.181, and 1.9 [0.3–21.9] vs. 0.9 [0.5–5.4] mg/L, P = 0.164, respectively).

According to the correlation analysis, there was no statistically significant correlation between biochemical parameters and Hcy or CRP values (P > 0.05). In subgroup analysis, the study group was divided into two subgroups according to BMI (BMI <25 vs. BMI ≥25), insulin resistance (HOMA-IR <2.1 vs. HOMA-IR ≥2.1), and clinical hirsutism (present vs. not present). There was no statistically significant difference in Hcy and CRP levels between subgroups (P > 0.05).

### Discussion

The main findings of the study were that many biochemical factors thought to cause CVD were higher in patients with PCOS. Hcy and CRP have been accepted as biochemical markers for possible future CVD. Most of the previous literature found that Hcy levels were higher in women with PCOS than in controls. This study also revealed higher Hcy levels in women with PCOS, but the difference was not statistically significant between study and control subjects. Similarly, CRP levels were higher in the study group, but the difference did not reach a statistical significance. Besides, there was no statistically significant correlation between two markers of concern and other biochemical/clinical variables.

PCOS, which is a frequent disease of reproductive-age women, is shown to have a correlation with long-term adverse health outcomes and cardiovascular disorders. There are available data suggesting the increased incidence of CVD in women with PCOS,[11] but the causality has not been elucidated in detail yet. There is a plenty of data in the literature concerning higher Hcy levels in women with PCOS. A meta-analysis concerning CVD markers in PCOS population, including 24 case–control and cross-sectional studies, reported that Hcy levels were statistically significantly higher in subjects with PCOS, although long-term outcomes of this descriptive conclusion were not known.[11] Another meta-analysis concerning levels of oxidative stress markers including Hcy in women with PCOS reported that the presence of PCOS was accompanied by a 23% increment in Hcy levels.[21]
Previous studies reported various interfering factors with Hcy levels such as, folate, Vitamin B6, and B12 levels, smoking status, medications such as antilipidemic drugs and genetic enzymatic deficiencies.[24-27] Interestingly, some of the studies[28-30] have not evaluated these intervening factors as a limitation which might be a possible explanation for conflicting results in the literature about the subject. These factors need to be taken into consideration while evaluating levels of Hcy before reaching clear conclusions. Furthermore, Hcy levels were shown to be higher in subjects with metabolic syndrome[31] which is a quite frequent clinical situation in women with PCOS. However, most of the literature did not adjust their findings for the presence of metabolic syndrome while evaluating Hcy levels. In addition, women with PCOS are classified in four different phenotypes with a different severity of metabolic and cardiovascular outcomes, and some clinical conditions such as metabolic syndrome were more prevalent among PCOS phenotypes with hyperandrogenism.[32] A relatively low number of subjects with clinical and biochemical hirsutism in the current study population might be another possible explanation for the higher but statistically unsignificant difference between the groups. Phenotyping women with PCOS in future studies might serve for more precise conclusions.

Besides CVD risk, high Hcy levels have been associated with adverse fertility outcomes such as lower oocyte and embryo quality, lower fertilization and implantation rates, and adverse fetal outcomes.[33] But also, it has been demonstrated that Hcy levels are significantly correlated with obesity and insulin resistance which have a role in causality of anovulatory infertility in women with PCOS.[34] In this study, there was no statistically significant correlation between Hcy levels and metabolic variables which might be attributed to the relatively normal BMI and young age of the included subjects.

As previously mentioned, CRP has been used to follow up low-grade inflammation which is correlated with CVD risk. A meta-analysis of 48 studies (case–control and cross-sectional) concerning CRP levels in women with PCOS reported that CRP levels were significantly higher in the study group.[11] Contradictory to these findings, although the mean CRP level in women with PCOS was higher than the control group in the current study, there was no statistically significant difference. A point that should be considered is that mean CRP levels of the study population (1.9 [0.3–21.9] mg/L) were classified as intermediate risk (1–3 mg/L)[17] and mean CRP values of the control group (0.9 [0.5–5.4] mg/L) would be classified as low risk (<1 mg/L)[17] if these values were taken into consideration for CVD risk assessment defined according to the Centers for Disease Control and Prevention and American Heart Association.[18] CRP levels were affected by the menstrual cycle[16,33] and most of the studies preferred to obtain blood sampling for CRP measurement with other biochemical parameters which were at the early days of the menstrual cycle. We also obtained blood samples in the 2nd and 3rd day of the menstrual cycle, but for both groups, excluding the possible intervening effect of the active menstruation on the CRP values.

Insulin resistance is associated with atherosclerotic processes.[36] Insulin resistance and obesity are seen in women with PCOS, but insulin resistance may be seen equally in both obese and nonobese women with PCOS.[37,38] In our study, insulin resistance levels were higher in women with PCOS than controls. Obesity is another contributing factor for CVD. It is accepted as one of the hallmarks of PCOS which becomes the risk factor for CVD in future.[39] Hcy is increased in both obese and nonobese women with PCOS in accordance with the findings of the current study.

Hyperandrogenism might a possible risk for CVDs. Free testosterone might be a major contributing factor to CVD risk.[40] In addition, abnormal lipid metabolism might be an important factor for CVDs. There were different results in the literature regarding dyslipidemia in women with PCOS. Some studies reported similar lipid parameters in women and PCOS and controls[19] while others reported higher triglyceride and lower HDL levels.[41,42] In our study, although lipid parameters were higher in PCOS, the difference did not reach statistical significance, which might be attributed to the normal mean BMI and young age of the subjects.

The limitations of this study might be evaluated under a few headings. First of all, it was a single-center study. The study consisted of a limited number of patients. Second, it was designed as a descriptive study rather than an interventional study searching for effects of those interventions. Finally, the cross-sectional design of the study does not let to conclude about long-term alterations in the variables of CVD risk.

**Conclusion**

Many factors important for the development of CVD, including Hcy and CRP, are increased in women with PCOS. Heterogeneous clinical presentation and multiple aspects of PCOS are possibly the main limitations to reach final clear conclusions. Therefore, more comprehensive studies on homogeneous study groups with long-term follow-up are needed.

**Financial support and sponsorship**

Nil.

**Conflict of interest**

There are no conflicts of interest.

**References**

1. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ.
The prevalence of polycystic ovary syndrome in a community sample assessed using contrasting diagnostic criteria. Hum Reprod 2010;25:544-51.

2. Palomba S, Santagni S, Falbo A, La Sala GB. Complications and challenges associated with polycystic ovary syndrome: Current perspectives. Int J Womens Health 2015;7:745-63.

3. Dahlgren E, Janson PO, Johansson S, Lapidus L, Öden A. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 1992;71:599-604.

4. Güzüküçük, et al. PEACE Investigators. Prognostic significance, et al. Meta-analysis of cardiovascular disease risk Endogenous reproductive hormones and et al. 20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Zorovski JK, Rumsberg KE, et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2000;20:2414-21.

5. Grodnitskaia EE, Kurtsier MA. Homocysteine metabolism in polycystic ovary syndrome. Gynecol Endocrinol 2012;28:186-9.

6. Grodnitskaya EE, Kurtser MA. Homocysteine metabolism in polycystic ovary syndrome. Gynecol Endocrinol 2012;28:186-9.

7. Forges T, Monnier-Barbarino P, Alberto JM, Guéant-Rodriguez RM, Daval JL, Guéant JL. Impact of folate and homocysteine metabolism on human reproductive health. Hum Reprod Update 2007;13:225-38.

8. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: A meta-analysis. JAMA 2002;288:215-22.

9. Toulis KA, Goulis DG, Mintziori G, Kintiraki E, Eukarpidis E, Mouratoglou SA, et al. Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome. Hum Reprod Update 2011;17:741-60.

10. Eikelboom JW, Lonn E, Genest J Jr., Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular disease: A critical review of the epidemiologic evidence. Am Intern Med 1999;131:363-75.

11. Humphrey LL, Fu R, Rogers K, Freeman M, Helfand M. Homocysteine level and coronary heart disease incidence: A systematic review and meta-analysis. Mayo Clin Proc 2008;83:1203-12.

12. Mezanno D, Muñoz X, Martínez C, Cuevas A, Panes O, Aranda E, et al. Vegetarians and cardiovascular risk factors: Hemostasis, inflammatory markers and plasma homocysteine. Thromb Haemost 1999;81:913-7.

13. Hague WM. Homocysteine and pregnancy. Best Pract Res Clin Obstet Gynaecol 2003;17:459-69.

14. Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular disease in the United States. Ann Intern Med 2003;138:891-7.

15. Wijeyaratne CN, Niranrarakumsar K, Bala AH, Barth JH, Sheriff R, Belchetz PE. Plasma homocysteine in polycystic ovary syndrome: Does it correlate with insulin resistance and ethnicity? Clin Endocrinol (Oxf) 2004;60:560-7.

16. Badawy A, State O, El Gawad SS, El Aziz OA. Plasma homocysteine and polycystic ovary syndrome: The missed link. Eur J Obstet Gynecol Reprod Biol 2007;131:68-72.

17. Maleedhu P, Vijayabaskar M, Sharma SS, Kodumuri PK, Devi DV. Status of homocysteine in polycystic ovary syndrome (PCOS). J Clin Diagn Res 2014;8:31-3.

18. Zhao MJ, Yang YH, Zhou SJ, Yuan D, Lu WH, Liang Xiao-wei, et al. Serum homocysteine and metabolic syndrome in middle-aged and elderly men. Zhonghua Nan Ke Xue 2016;22:138-42.

19. Barber TM, Wass JA, McCarthy MJ, Franks S. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: Implications for the management of polycystic ovary syndrome. Clin Endocrinol (Oxf) 2007;66:513-7.

20. Ebisic IS, Thomas CM, Peters WH, Brant DD, Steegers-Theunissen RP. The importance of folate, zinc and antioxidants in the pathogenesis and prevention of subfertility. Hum Reprod Update 2007;13:163-74.

21. Fedorcsák P, Dale PO, Anderson JL, Cannon RO 3rd, Criqui M, et al. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.

22. Sabatine MS, D'Angelo A, Copolla A, Madonna P, Fermo I, Pagano A, Mazzola G, et al. The role of vitamin B12 in fasting hyperhomocysteinemia and its interaction with the homozygous C677T mutation of the methylenetetrahydrofolate reductase (MTHFR) gene: A case-control study of patients with early-onset thrombotic events. Thromb Haemost 2000;83:563-70.

23. Gaustadnes M, Rüdiger N, Rasmussen K, Ingerslev J. Intermediate and severe hyperhomocysteinemia with thrombosis: A study of genetic determinants. Thromb Haemost 2000;83:554-8.

24. Gómez-Bermejo A, Jutjens M, Nettleton J, Whelton PK. Relationship between cigarette smoking and novel risk factors for cardiovascular disease. Prev Med 2003;38:233-44.

25. Forges T, Monnier-Barbarino P, Alberto JM, Guéant-Rodriguez RM, Daval JL, Guéant JL. Impact of folate and homocysteine metabolism on human reproductive health. Hum Reprod Update 2007;13:225-38.

26. Mezanno D, Muñoz X, Martínez C, Cuevas A, Panes O, Aranda E, et al. Vegetarians and cardiovascular risk factors: Hemostasis, inflammatory markers and plasma homocysteine. Thromb Haemost 1999;81:913-7.

27. Hague WM. Homocysteine and pregnancy. Best Pract Res Clin Obstet Gynaecol 2003;17:459-69.

28. Blake GJ, Ridker PM. Inflammatory biomarkers and cardiovascular disease risk prediction. J Intern Med 2002;252:283-94.

29. Gursoy AS, Alphs LB, Deuschle LW, D'Agostino RB, Sr., Kannel WB, et al. Plasma homocysteine and carotid intima-media thickness in women: The Framingham Heart Study. JAMA 2000;283:1580-5.

30. Fedorcsák P, Dale PO, Anderson JL, Cannon RO 3rd, Criqui M, et al. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.

31. Sabatine MS, Morrow DA, Jablonski KA, Rice MM, Warnock JC, Domanski MJ, et al. PEACE Investigators. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation 2007;115:1528.

32. Cahyaoglu S, Yusufoğlu OH, Ozcer S, Pelcan MK, Erel M, Cicek MN, et al. Clomiphene citrate treatment cycle outcomes of polycystic ovary syndrome patients based on basal high sensitive C-reactive protein levels: A cross-sectional study. Int J Fertil Steril 2017;10:320-6.

33. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.

34. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.

35. Hedayat B, Nilsson P, Engström G, Berglund G, Janson L. Insulin resistance in non-diabetic subjects is associated with increased incidence of myocardial infarction and death. Diabet Med 2002;19:470-5.

36. Coskun A, Ersoy O, Ikiz MA, Kilinc M, Kuran G, et al. Modified Ferriman-Gallwey hirsutism score and androgen levels in Turkish women. Eur J Obstet Gynecol Reprod Biol 2011;154:167-71.

37. Murri M, Luque-Ramirez M, Insenser M, Ojeda-Ojeda M, Escobar-Morreale HF. Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): A systematic review and meta-analysis. Hum Reprod Update 2013;19:268-88.

38. Kang SS. Critical points for determining moderate hyperhomocyst(e)inaemia. Eur J Clin Invest 1995;25:806-8.

39. D’Angelo A, Copolla A, Madonna P, Fermo I, Pagano A, Mazzola G, et al. The role of vitamin B12 in fasting hyperhomocysteinemia and its interaction with the homozygous C677T mutation of the methylenetetrahydrofolate reductase (MTHFR) gene: A case-control study of patients with early-onset thrombotic events. Thromb Haemost 2000;83:563-70.

40. Maleedhu P, Vijayabaskar M, Sharma SS, Kodumuri PK, Devi DV. Status of homocysteine in polycystic ovary syndrome (PCOS). J Clin Diagn Res 2014;8:31-3.

41. Zhao MJ, Yang YH, Zhou SJ, Yuan D, Lu WH, Liang Xiao-wei, et al. Serum homocysteine and metabolic syndrome in middle-aged and elderly men. Zhonghua Nan Ke Xue 2016;22:138-42.